The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer.

The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer.
复制标题

卵巢癌免疫检查点阻断的预测和预后生物标志物的现状

DOI:
10.3389/fimmu.2022.1045957
复制
发表时间:
2022
影响因子:
7.3
通讯作者:
He, Xiujing
He, Xiujing
中科院分区:
医学2区
文献类型:
--
作者:
Xu, Yufei;Zuo, Fengli;Wang, Huiling;Jing, Jing;He, Xiujing

文献摘要

参考文献

相似文献

免疫检查点阻断(ICB)治疗引起了抗癌治疗的显著转变。在卵巢癌(OC)患者中观察到ICB的持久临床抗肿瘤活性。然而,只有一小部分患者会获得临床益处,ICB治疗引起的免疫相关不良事件(IrAEs)可能会导致永久性的组织损伤,甚至是致命的后果。因此,迫切需要开发预测性生物标志物,以优化患者结局并将毒性风险降至最低。在这里,我们回顾了目前用于OC检查点免疫治疗的预测和预后生物标记物,并重点介绍了指导ICB治疗的新兴生物标记物。进一步讨论了PD-L1表达状态、肿瘤浸润性淋巴细胞、突变负荷和免疫基因特征等流行的生物标志物。我们提供了检查点免疫治疗的预后和预测生物标志物的最新进展,并为指导精确的免疫治疗提供了有价值的信息。
Immune checkpoint blockade (ICB) therapy has evoked a prominent shift in anticancer therapy. Durable clinical antitumor activity to ICB has been observed in patients with ovarian cancer (OC). However, only a subset of patients derive clinical benefit, and immune-related adverse events (irAEs) caused by ICB therapy can lead to permanent tissue damage and even fatal consequences. It is thus urgent to develop predictive biomarkers to optimize patient outcomes and minimize toxicity risk. Herein, we review current predictive and prognostic biomarkers for checkpoint immunotherapy in OC and highlight emerging biomarkers to guide treatment with ICB. The prevalent biomarkers, such as PD-L1 expression status, tumor-infiltrating lymphocytes, mutational burden, and immune gene signatures, are further discussed. We provide a state-of-the-art survey on prognostic and predictive biomarkers for checkpoint immunotherapy and offer valuable information for guiding precision immunotherapy
卵巢癌的免疫细胞浸润情况可识别预后和免疫治疗相关基因以辅助免疫治疗
DOI: 10.3389/fcell.2021.749157
发表时间: 2021
影响因子: 5.5
作者:
Li X;Liang W;Zhao H;Jin Z;Shi G;Xie W;Wang H;Wu X
通讯作者: Wu X
DOI: 10.3389/fgene.2022.905238
发表时间: 2022
影响因子: 3.7
作者:
通讯作者: --
PD-1和PD-L1抑制剂作为癌症免疫疗法的一种形式的开发:对注册试验和未来考虑的全面综述。
DOI: 10.1186/s40425-018-0316-z
发表时间: 2018-01-23
影响因子: 10.9
作者:
Gong J;Chehrazi-Raffle A;Reddi S;Salgia R
通讯作者: Salgia R
DOI: 10.1080/15384047.2020.1824479
发表时间: 2020-10-11
影响因子: 3.6
作者:
Liu, Fangran;Liu, Jiao;Xu, Guoxiong
通讯作者: Xu, Guoxiong
DOI: 10.1038/s43018-020-0096-5
发表时间: 2020-09-01
期刊: NATURE CANCER
影响因子: 22.7
作者:
Bratman, Scott V.;Yang, S. Y. Cindy;Pugh, Trevor J.
通讯作者: Pugh, Trevor J.